Table 1.
Number of individuals tested, testing rates and positivity
| Indicator condition | Baseline audit HIV test rate (Individuals tested/ seen) | Pilot Individuals seen | Pilot Individuals tested for HIV | Pilot Individuals testing positive | Pilot HIV test rate | Pilot HIV positivity | Baseline audit HCV test rate (Individuals tested/ seen) | Pilot Individuals tested for HCV | Pilot Individuals testing positive | Pilot HCV positivity | Pilot HCV test rate | Pilot Individuals tested for HBV | Pilot Individuals testing positive | Pilot HBV positivity | Pilot Individuals tested for STIs | Pilot Individuals testing positive | Pilot STI positivity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Established IC HIV prevalence of > 0.1% | |||||||||||||||||
| STI | 37.4% (375/1002) | 1643 | 1592 | 1 | 97% | 0,06% | 0.8% (9/1104) | 921 | 5 | 0.54% | 98% | 452 | 2 | 0.44% | |||
| Herpes simplex (labialis) | 0% (0/55) | 105 | 45 | 0 | 43% | 0% | NA | 19 | 0 | 95% | |||||||
| Herpes zoster | 0% (0/48) | 44 | 27 | 1 | 61% | 3.70% | NA | 14 | 0 | 93% | |||||||
| Seborrheic dermatitis | 2.2% (5/223) | 357 | 206 | 1 | 58% | 0,49% | NA | 91 | 0 | 58% | |||||||
| Severe psoriasis | 0.5% (10/2090) | 2534 | 1523 | 0 | 60% | 0% | NA | 567 | 3 | 0.53% | 95% | ||||||
| Candidiasis (oral) | 3.3% (12/360) | 478 | 271 | 0 | 57% | 0% | NA | 89 | 0 | 57% | |||||||
| All dermatovener rological IC | 10.6% | 5161 | 3664 | 3 | 71% | 0.08% | NA | 1701 | 8 | 0.47% | NA | ||||||
| Tuberculosis | 67.4% (295/438) | 308 | 260 | 2 | 84% | 0,77% | |||||||||||
| *Total established IC | NA | 5469 | 3924 | 5 | 72% | 0.13% | |||||||||||
| New ICs included | |||||||||||||||||
| Chemsex | NA | 170 | 9 | 0 | ***5% | 0 | NA | 117 | 4 | 3.4% | 69% | 117 | 61 | 52% | |||
| Alcohol dependency | NA | NA** | 946 | 3 | NA | 0,3% | NA | 926 | 34 | 3.67% | NA | ||||||
*All dermatovenerological IC and Tuberculosis
**Individuals seen is not available, individuals attending treatment are reported as visits and one individual has several visits during treatment
***Most chemsex-users where known HIV positive